Tumor suppressor candidate 2 (TUSC2) nanovesicle-based immunogene therapies, when combined with anti-PD-1 therapy, were shown to significantly inhibit tumor growth and extend survival in mouse models of Kras-mutant lung cancer [103]. Here, PDCD1 is linked to lung carcinoma.